सत्यमेव जयते

Supported by
Ministry of Commerce & Industry
Government of India

pharmexcil

Pharmaceuticals Export Promotion Council of India
(Setup by Ministry of Commerce & Industry, Govt. of India)

14th Annual Report
2017 - 18



BE INDIA
Pharmacy of the World

Contents of Annual Report 2017-18

S.No.	Subject	Page No.
1.	Notice for the Meeting	3
2.	Membership	5
3.	Committee of Administration	9
4.	Performance of Indian Pharma Industry	13
5.	Export Promotional Activities	19
6.	Accounts	53
7.	Circulars & Trade Enquiries	73
8.	Beneficiaries under MAI Scheme	81

PXL/HO/Cir-043/2018-19 Date: 24th August 2018
Hyderabad

To
All the Members of the Council

NOTICE

NOTICE is hereby given that the 14th Annual General Meeting of the Council will be held on 14th September, 2018, at 1730 hours at Hotel Taj Krishna, Banjara Hills, Hyderabad to transact the following ordinary business/Agenda:

1. To receive and consider the account and the reports of the Committee and the auditors for the year ending 31st March, 2018.

   The reports of Auditors on the Accounts of the Council for the Financial Year ending March 31, 2018 and the report of the Committee (CoA) on the activities of the Council for the year 2017-18 are enclosed

2. To place on record the names of the Committee members

   The details of the Members of the Committee of Administration (CoA) with the nature of their Membership indicated against their names are attached.

3. To appoint and fix the remuneration of the auditors.

   M/s. Sarath & Associates, appointed as Statutory Auditors of the Council will retire on the conclusion of the Annual General Meeting and they being eligible offer themselves for reappointment

For and on behalf of Committee of Administration

Udaya Bhaskar
Director General

MEMBERSHIP

MEMBERSHIP

State wise Registered Companies up to the Financial year 2017-18

State	No. of Regd. Companies
Andhra Pradesh	39
Assam	2
Bihar	10
Chandigarh	42
Chattisgarh	2
Delhi	359
Goa	8
Gujarat	591
Haryana	89
Himachal Pradesh	32
Jammu	7
Karnataka	185
Kerala	34
Madhya Pradesh	75
Maharashtra	1664
Nagaland	1
Orissa	4
Punjab	52
Rajasthan	50
Tamil Nadu	205
Telangana	479
Uttar Pradesh	71
Uttaranchal	25
West Bengal	43
Total	**4069**

Category Wise Registered Companies

Category	
LSM	373
SSM	1966
ME	1730
Grand Total	**4069**

Panel Wise-Registered Companies

Panel Wise	Description of Panel	No. of Members
Panel-1	Pharmaceutical Formulations (Including Nutraceuticals, Excipients, Surgicals and Diagnostics, Veterinary Products etc)	**1060**
Panel-2	Bulk Drugs & Drug Intermediates	**762**
Panel-3	Herbal Products (Including Ayurvedic, Homeopathic, Unani & Siddha Medicines)	**274**
Panel-4	Biotech Products	**24**
Panel-5	Pharmaceutical Services (Including R & D, Clinical Trials, Medical Transcripts)	**77**
Panel-6	Healthcare Services	**87**
Panel-7	Merchant Exporters (Traders, CROs)	**1785**
	Total	**4069**

COMMITTEE OF ADMINISTRATION

Committee of Administration

Chairman

Sri Madan Mohan Reddy
Director
Aurobindo Pharma Limited

Vice Chairman

Sri Dinesh Dua
CEO & Director
Nectar Life Sciences Limited

Government Nominees

Sri Shyamal Misra, IAS Jt. Secretary Department of Commerce Ministry of Commerce & Industry Government of India	**Sri Sudhansh Pant** Jt. Secretary Department of Pharmaceuticals Ministry of Chemicals & Fertilizers Government of India
Dr. K L Sharma Jt. Secretary Department of Health Ministry of Health & Family Welfare Government of India	**Dr. T S Rao** Advisor / Scientist - G Department of Biotechnology Ministry of Science & Technology Government of India

Elected Members

Sri Devang B Shah Director Aadivighnesh Chem Pvt Ltd Mumbai	**Sri Bharat Desai** Managing Director Bharat Parenterals Limited Vadodara
Sri Tushar A Korday Director Emil Pharmaceutical Industries Pvt Ltd Mumbai	**Dr. A.R. Venkatesh** Chief Executive Officer Global Pharma Healthcare Private Limited Chennai
Sri Sandeep V Bambolkar Jt. Managing Director Indoco Remedies Ltd Mumbai	**Sri Sahil Munjal** President & Chief Executive Officer Ind-Swift Laboratories Ltd Chandigarh
Sri Bhavin Patel Partner Mediwin Pharmaceuticals Ahmedabad	**Sri Atul Bhopale** Executive Director Nexgen Healthcare Pvt Ltd Mumbai

Elected Members	
Sri Dodda VVS Reddy Director Nosch Labs Limited Hyderabad	**Dr. Janmejay H Patel** Chief Executive Officer Petlad Mahal Arogya Mandal Pharmacy Nadiad
Sri P Ramesh Babu Chairman & Managing Director SMS Pharmaceuticals Limited Hyderabad	**Sri Vijay Shah** Managing Director Stallion Laboratories Pvt ltd Ahmedabad
Sri Siddharth Daga Executive Director Vins Bioproducts Ltd Hyderabad	

Ex-Officio Members / National Associations	
Dr. P M Murali President Association of Biotechnology Led Enterprises (ABLE)	**Sri Chandrakant Bhanushali** President Ayurvedic Drug Manufacturer's Association (ADMA)
Sri VV Krishna Reddy President Bulk Drug Manufacturer's Association (BDMA) Hyderabad	**Sri Deepnath Roy Chowdhury** President Indian Drug Manufacturer's Association (IDMA) Mumbai
Sri Nilesh Gupta President Indian Pharmaceuticals Alliance (IPA) Mumbai	

Sri Udaya Bhaskar
Director General & Member Secretary

PERFORMANCE OF INDIAN PHARMA INDUSTRY

Indian Pharmaceutical Industry In 2017-18 - An Overview

India's Exports of Pharmaceuticals:

India's Exports of Pharmaceuticals in 2017-18 has been to a tune of $ 17.27 billion and has the following composition.

Drug formulations & Biologicals is the third largest among the principal commodities exported by India during 2017-18.

India's Exports During April - March $ million				
Category	**Fy-17 $ mn**	**Fy-18 $ mn**	**Growth%**	**Contbn%**
Ayush	124	144	16.73	0.84
Bulk Drugs And Drug Intermediates	3,384	3,540	4.61	20.49
Drug Formulations and Biologicals	12,666	12,909	1.91	74.72
Herbal Products	278	312	12.04	1.80
Surgicals	333	372	11.53	2.15
Grand Total	**16,785**	**17,276**	**2.92**	**100.00**

Exports by Region

Region wise India's pharma exports during April-March $ million				
Region	**Fy-17**	**Fy-18**	**Gr%**	**Contbn%**
North America	5770	5346	-7.35	30.95
Africa	3214	3347	4.14	19.37
EU	2523	2750	9.02	15.92
Asean	1083	1181	9.07	6.84
LAC	993	1135	14.33	6.57
Middle East	808	869	7.60	5.03
South Asia	722	764	5.81	4.42
CIS	632	733	16.02	4.24
Asia (Excluding Middle East)	565	627	10.83	3.63
Oceania	297	320	7.71	1.85
Other European Countries	130	151	16.34	0.87
Other America	48	52	10.13	0.30
Others	1	0	-97.77	0.00
Grand Total	**16785**	**17276**	**2.92**	**100.00**

Pictorial Representation of India's exports in 2017-18.



Salient Features

1) Contribution of Indian pharma industry in Global pharma production : 10% in terms of volume & 2.49% in terms of value.
2) India produces 65% of WHO demand for DPT & BCG and 90% of Measles vaccine.
3) 8 out of top 20 global Generic companies are from India.
4) India's Pharma exports Fy-18 has recorded an average of $ 80.35 million during the period per destination. Total number of Destinations during the period is 215.
5) Exports to 129 destination countries are growing.
6) Around 55% India's exports are to highly regulated markets like North America and Europe. USA is the largest exporting partner of India by country.
7) India shares 50% of Africa's Generic market value of $ 6000 million.

India's Pharma Exports to Top 30 countries during 2015-18 $ million

Rank	Country	2015-16	2016-17	2017-18	Growth %	% Contribtn by Value
1	U S A	5514	5564	5116	-8.04	-447
2	SOUTH AFRICA	605	485	583	20.23	98
3	U K	564	550	557	1.25	7
4	RUSSIA	374	383	469	22.24	85
5	NIGERIA	437	398	467	17.26	69
6	GERMANY	348	333	388	16.54	55
7	BRAZIL	326	337	384	13.74	46
8	KENYA	332	325	255	-21.76	-71
9	AUSTRALIA	233	237	254	7.15	17
10	FRANCE	232	209	251	20.38	43
11	BELGIUM	192	231	243	5.07	12
12	NETHERLAND	244	203	234	15.33	31
13	NEPAL	177	207	233	12.47	26
14	CANADA	201	207	230	11.23	23
15	VIETNAM SOC REP	221	227	226	-0.36	-1
16	PHILIPPINES	193	208	217	4.00	8
17	SRI LANKA DSR	205	217	207	-4.82	-10

18	CHINA PRP	146	145	200	37.52	55
19	TANZANIA REP	179	196	186	-5.26	-10
20	MYANMAR	154	186	182	-2.35	-4
21	TURKEY	160	166	173	4.62	8
22	THAILAND	148	141	173	22.37	32
23	MEXICO	160	157	165	4.61	7
24	BANGLADESH PR	136	154	162	5.78	9
25	UGANDA	169	154	156	1.47	2
26	ITALY	123	124	153	23.52	29
27	JAPAN	144	168	147	-12.33	-21
28	PAKISTAN IR	102	129	142	9.59	12
29	SPAIN	134	124	141	13.97	17
30	INDONESIA	69	97	141	44.82	44
	Total of top30	12221	12263	12433	1.38	170
	Grand Total	**16912**	**16785**	**17276**	**2.92**	**491**

Regulatory Approvals for Indian Pharmaceuticals:

India's Pharmaceutical industry has filed the highest number of DMFS with USFDA and by the end of July 2017, the number of filings stands at 3980. India's ANDAS totaling 4325 by March 2018 covers all ATCs. Following Table gives an overview of India's Accreditations.

Authority	Name of Regulatory Agency	Nos.
USA	DMFs filed with U.S. FDA (companies) (as on 31st July 2017)	**195**
	No: of Sites (Bulk drugs + Formulations) Registered with US FDA (as on April 2018)	**700**
	Total No of DMF's (Type II Active) Filed by India companies (as on 31st July 2017)	**3980**
	ANDAs market Authorizations (As on March 2018)	**4325**
	Formulation companies with USFDA approvals.	**53**
EUROPE	Number of CEPs received (as of Feb 2018)	**1597**
	Number of companies with CEPs	**194**
	Number of Molecules for which CEPs have been filed with EDQM	**426**
	No of Sites with EU GMP Compliance as on April 2018	**769**
	UK MHRA (Medicines Healthcare Regulatory Agency), Market authorizations as on March 2018	**1950**
	Number of CEPs with Irish Medicines Board	**300**
	Number of companies registered in Irish Medicines Board	**19**
	Number of Authorisations with Sweden MPA (Läkemedelsverket)	**209**
	Number of companies having MA`s with Sweden MPA (Läkemedelsverket)	**14**
WHO GMP	WHO GMP Certified Plants (as per Drug Controller General of India)	**1400 (approx.)**
Ethiopia	DACA (Drug Administration and Control Authority), Ethiopia (companies)	**50**
Tanzania	(TFDA) Tanzania Food and Drugs Authority (companies)	**1373**

EXPORT PROMOTIONAL ACTIVITIES

EXPORT PROMOTIONAL ACTIVITIES
ABROAD 2017 -18

PHARMACONEX EGYPT

Council organized India Pavilion at Pharmaconex, Egypt held during 8-10th April 2017. Nineteen Indian companies participated in the event. This was organized by Council with its own fund support.

CPhI CHINA

Council organized India Pavilion at CPhI China during 20-22nd June 2017. Council continued to participate in this event on its own, as the response from members is good. 20 companies participated in India Pavilion. Consul General of Indian Embassy in China inaugurated the pavilion.

iPHEX LATAM IN PERU

3rd edition of iPHEX LATAM was organized by Council at Peru, which was preceded by business meetings in Columbia, El-Salvador during 27th August to 9th September 2017.

CPhI WORLD WIDE

Council organized India Pavilion in this mega pharma event for the 12th time. The pavilion was located in four halls, two halls focused for APIs and two halls focused for finished formulations. 52 member companies participated in the pavilion. India Pavilion at CPhI Worldwide was inaugurated by the Chief Guest Ms.Pratibha Parkar, Consul General, Consulate General of India and Guest of Honour Mr.Shyamal Misra, IAS, Joint Secretary, Ministry of Commerce & Industry at Frankfurt on 24th October 2017. Chairman, Vice Chairman, some of the CoA members, Director General, Regional Director AKS), Dy. Director from Pharmexcil, Brand Pharma Director of UBM, industry representatives attended the inaugural function. As part of Brand India Pharma activity, IBEF and Pharmexcil organized the Summit on 24th October 2017 at Pharma Forum. A Panel Discussion on "Accessibility of Affordable Medicines: Cost of Regulation vis-vis-Cost of Medicines" is organised with participation of the Eminent Panelists from IMS Health, USAID, Clarivate Analytics, Sun valley Communication and Nectar Lifesceinces.



ARAB HEALTH 2018

Council organized India Pavilion in this important event for the 12th consecutive year during 28-31st January 2018. This year the organizers have allotted one single hall for Indian companies. Pharmexcil and EEPC organized pavilions in this exhibition in about 850 sq. meters area and over Indian companies participated. Senior officials from Consulate office of Indian embassy in Dubai have inaugurated the pavilion.

BUSINESS MEETINGS IN AFRICAN COUNTRIES

A Business delegation to DR Congo, Nigeria and Cote d'ivoire was organized during 18-28th February 2018. 49 Indian companies participated in the event. This is the first time that Council organized such a huge business delegations to DR Congo, Nigeria and Cote d'ivoire.

BSM in DR Congo - 20th February 2018

BSM in Nigeria - 22nd February 2018

BSM in Cote d'ivoire - 27th February 2018

EXPORT PROMOTIONAL ACTIVITIES

INDIA 2017 -18

iPHEX

5th edition of iPHEX was held in Hyderabad during 27-29th April 2018. Shri K T Rama Rao, Hon'ble Minister for IT, Industries Commerce, Telangana Govt. was the Chief Guest for the inauguration of the event. Shri S Eshwar Reddy, Jt. Drugs Control General (I), Hon'ble Minister for Health, Ghana were the other dignitaries participated in the inaugural function. Over 650 hosted buyers, 10,000 visitors, 300 exhibitors participated in the event. Apart from 650 hosted buyers, more than 200 overseas visitors attended the show on their own. Following events were organized during the 3 days of the show:

- Exhibition
- B2B meetings among exhibitors and overseas delegates
- Technical seminars on drug regulations in India, overseas, international procurement practices for Vaccines etc.
- Innovation Lounge – Invited all Government Research institutes in India and arranged interaction between Labs & industry
- Regulators Lounge – Arranged meetings among international regulators and exhibitors/visitors.

Inauguration of 5th edition of iPHEX-2017 by

Sri K.T. Ramarao, Minister for Information Technology, Municipal Administration and Urban Development, Industries & Commerce, Mines & Geology, Public Enterprises and NRI Affairs (Government of Telangana)

Inauguration of Stalls

B2B Meetings at iPHEX

Technical sessions at iPHEX

Stalls at iPHEX

OUTREACH PROGRAMME BY MEA

Ministry of External Affairs had organized an Outreach programme in the State of Telangana on 13th May 2017 at Hyderabad. Director General attended the meeting and explained problems of some of the exporters relating to visas. Hon'ble Minister and Secretary enquired about EPCs activities in overseas and role of missions in promotion of exports. At the instance of Secretary, MEA, Secretariat submitted a brief note on expectations of EPCs from embassies.

SYMPOSIUM ON "REGULATOR TO FACILITATOR"

IPA, in association with AIDCOC and Pharmexcil, organized a symposium on 'Regulator to Facilitator' on 10th June 2017 at Hyderabad. Senior officials from CDSCO, NIB, State Drug Administration, AIDCOC and industry participated and interacted with the participants.

SEMINARS ON GST

IDMA-TS branch, in association with Pharmexcil, organized a half day seminar on 'GST for Pharma industry' on 19th June 2017 at Hyderabad. Superintendent of Customs & Central Excise, Hyderabad, two consultants on the subject, industry professionals made presentations about overview of GST, major changes in taxation in GST regime, expected legal issues etc. Over 80 members participated and got their queries clarified.

SEMINAR ONGST - IMPACT ON PHARMA SECTOR

Council organized a Seminar on GST and impact on Pharma sector at Mumbai on 27th June 2017. Senior officials from Customs, Navsheva, DGFT have attended and interacted with the participants. Over 120 member companies actively participated in the event.

MEETING WITH DEPUTY PRIME MINISTER OF VIETNAM

During the visit of Deputy Prime Minister of Vietnam to Delhi on 5th July 2017, Director General met him and submitted a presentation on the various issues raised by Indian companies operating in Vietnam.

AWARENESS PORGAMME ON AYURVEDIC PRODUCTS

Pharmexcil actively participated in an Awareness programme for Ayurvedic Manufactuters and exporters on quality Parameters and International Marketing for AyurvedicProducts , jointly organised by Federation of Indian Export Organisations and the Office of the Joint Director General of Foreign Trade, Kochi on 6th July 2017.

PHARMA SOUTH

Council participated in the Pharma South 2017 expo organized by IDMA, Tamil Nadu, Puduchery & Keral State Board at Chennai during 7-8th July 2017.

8TH INDIA-EU JOINT WORKING GROUP MEETING, NEW DELHI

8th India-EU Joint Working Group Meeting was organized by Department of Pharmaceuticals, during 13-14th July 2017 at Delhi. Council provided inputs for the meeting and also actively participated in the meeting.

INVESTMENTS IN CHELYABINSK REGION

Chelyabinsk Region of Russia has requested Indian Government for its support in investments in pharmaceutical sector in their region. Council organized an interactive meeting on 17th July 2017 at Hyderabad between interested members and senior officials of Department of Commerce. About 20 members participated. Some of the members sought additional information, which was communicated to DoC for taking up with the concerned in Russia.

YOUNG PARLIAMENTARIANS FAMILIARIZATION PROGRAMME

Thirty Three (33) Young Parliamentarians from different countries of Africa have visited India during first week of August 2017 to familiarize with trade, cultural, political aspects of India. Council organized an interactive meeting with these parliamentarians on 5th August 2017 at Mumbai.

TRAINING PROGRAMME ON FOREIGN TRADE WITH GST PERSPECTIVE

Post implementation of GST, many members were sending several queries about procedures of GST. In order to clarify the queries of members, Council organized training programme at Mumbai on 11th August 2017.



EXTRA-ORDINARY GENERAL MEETING OF COUNCIL

To get the approval of general body for some of the amendments to the Articles of Association, extra-ordinary meeting of general body was held on 29th August 2017 at Hyderabad.

INTERACTIVE MEETING WITH RBI OFFICIALS ON EDPM SCHEME

In association with FIEO, Council organized an interactive meeting on Export Data Processing and Monitoring System on 13.9.2017 at Hyderabad. It was well attended by our members. The officials from RBI has clarified most of the queries raised by the members and in case of problems where banks also to be present, he advised the members to meet him along with their bankers to resolve the issues. Similar programme will be conducted at Mumbai also soon.

INTERACTIVE MEETING WITH DGFT

Under DGFT's Niryat Bandhu Initiative, Council organized an interactive meeting on 15th September 2017 at New Delhi for the benefit of members in northern region. Senior officials from DGFT office have participated and over 70 companies interacted with the DGFT officials.

EXPORT COMMITTEE MEETING

Under the chairmanship of Dr. Hashmukh Adiya, Revenue Secretary, a committee on Exports was constituted. First meeting of the Committee was held on 19th Sep 2017 at Delhi. Commerce Secretary, Chief Economic Advisor, GST commissioners of various States, representatives of EPCs attended the meeting. Council actively participated in the meeting.

FOREIGN TRADE WITH GST PERSPECTIVE

Post implementation of GST, many members were sending several queries about procedures of GST. In order to clarify the queries of members, Council organized training programme at Bengaluru on 20th September 2017.

13TH ANNUAL MEET OF COUNCIL

On the eve of 13th Annual Meet of Council, following activities have been organized:

Round Table Conference – Crucible to Market – Senior officials from CSIR laboratories, DCGI, Department of Biotechnology, Pharma and over 60 industry representatives have actively participated.

Technical Seminar - "Risk Management Strategy for Pharma Industry Going Forward",

13th Statutory Annual General Meeting

CEOs Conclave:

CEOs of Laurus Laboratories Ltd, Hospira Healthcare, Eisai, Joint Secretary, Department of Commerce, Chairman and Vice Chairman of Pharmexcil participated in the CEO Conclave. The Theme of the Conclave was **"Need of the Hour to Sustain Positive Growth of Indian Pharma Industry".** Executive Vice President of GSK Pharma Healthcare was the moderator of the Conclave.

Felicitation to Dr. P V Appaji, Director General of Council, who retired after serving Council for 13 years.

9th Edition of Outstanding Export Performance Awards, Hyderabad

INTERACTIVE MEETING WITH EDITORS FROM LAC REGION

Council organized an interactive meeting with 33 senior Editors / Journalists from LAC Region, at Mumbai on 06 October 2017.

INTERACTIVE MEETING WITH HIGH LEVEL DELEGATION FROM IRAQ

A high level Iraqi delegation led by Honb'le Health Minister Ms. AdeelahSaleem and key representatives from the Ministry of Health, Republic of Iraq visited India during 11-14th October 2017. An interactive session was organized by Pharmexcil on 12th October 2017 between the member companies and the visiting delegation for discussing the market related issues and exploring the opportunities of trade between the countries. Shri Sudhansu Pant, Joint Secretary, Department of Pharmaceuticals was the Chief Guest of the occasion.

INTERACTIVE MEETING WITH MERCHANT EXPORTERS

In order to understand the problems & impediments faced by our member-exporters, Council organized an Interactive Meeting of Merchant Exporters segment on 23.10.2017 at Mumbai, so as to take effective measures for representing the issues / problems / impediments at the highest level with the Government. The meeting was attended by over 120 industry representatives.

INTERACTIVE MEETING ON GST AT HYDERABAD

Council organized an interactive meeting with the Commissioner, GST, Hyderabad on 3rd November 2017 at Hyderabad for the benefit of members from AP and Telangana States. About 60 members participated and got their queries clarified. Senior officials from Hyderabad GST Commissionrate, Dr. P V Appaji and Shri Udaya Bhaskar, Director General have participated in the meeting.

HIGH-LEVEL DELEGATION TO CUBA AND PANAMA

A high level delegation led by Hon'ble Minister for Commerce, was organized FIEO during 27th September – 4th October 2017. Shri Syamal Misra, Joint Secretary, Shri Dammu Ravi, Joint Secretary are part of the high-level delegation. Council participated in the delegation and interacted with the officials of Ministry of Health, Govt. of Cuba.

MEETING WITH HON'BLE MINISTER OF COMMERCE

On 7th November, Pharmexcil met Hon'ble Minister for Commerce Minister and H.E. Ambassador, Embassy of India, Russia and CDSCO at New Delhi.

CPhI INDIA

Council organized a Pavilion at CPhI India for the 12th time, during 28-30th November 2017. 106 companies participated in the pavilion. Pavilion was inaugurated by Commissioner, FDA, Maharashtra. Senior officials from CDSCO, Chairman, Vice Chairman and some of the members of CoA attended the inaugural function.

Advisor to the Prime Minister of Cote d'ivoire along with Consular in India attended the exhibition. Council arranged meetings with some of the CoA members, companies exhibiting in CPhI. The objective of her meeting is to encourage investments in their country. She promised to arrange for a meeting with Prime Minister when Council organizes BSMs in Feb 2018.

INTERNATIONAL AROGYA

FICCI & Pharmexcil jointly organized the first edition of International AROGYA 2017, an International Exhibition & Conference on AYUSH & Wellness during 4-7 Dec.2017 at New Delhi. The event is supported by Ministry of AYUSH and Ministry of Commerce & Industry. Pharmexcil has invited 70 overseas delegates and FICCI invited 130 overseas delegates for the event and organized two-day Buyer Seller Meeting. The three-day conference discussed on potential markets for AYUSH industry, prevailing issues relating to exports and regulatory practices of various countries.

INTERACTIVE MEETING WITH HIGH LEVEL DELEGATION FROM CUBA

As a follow up of our meetings in Cuba in Sep 2017, a high level official delegation led by the Honorable Minister of Public Health of the Republic of Cuba, H.E Dr. Roberto Morales Ojeda and accompanied by the Vice President of the Group of Companies BIOCUBAFARMA, Ms. Mayda Mauri Perez visited India during 6-7th December 2017. Council organized an interactive meeting with these officials at Delhi on 7th December 2017.

SEMINAR ON SHIFTING INDUSTRY FROM SCHEDULE M TO WHO GMP

IDMA and Department of Pharmaceuticals have organized a seminar on "Shifting Industry from Schedule M to WHO GMP on 8th December 2017. Senior officials of CDSCO, State Drug Administration of Telangana also have participated in the seminar. Since the topics covered are important to the members, Council supported the event and actively participated.

INTERACTIVE MEETING WITH HIGH COMMISSIONER OF GHANA

IPA and Pharmexcil jointly organized an interactive meeting with H.E. Mr. Michael Aaron. N.N. OquayeEsq (Jnr), High Commissioner, Republic of Ghana at Hyderabad on 18th January 2018.

WORKSHOP IN ASSOCIATION WITH ICSSR

In association with ICSSR, Council organized a one-day workshop on 23 January 2018 on " Pathways to Outsourcing and Contracting, Pharmaceutical Manufacturing in India and Implications for Industrial and Technological Upgrading, ISID (ICSSR) at New Delhi.

INTERACTIVE MEETING WITH MINISTER OF TRADE & INDUSTRY, PHILIPPINES

Philippines Trade & Investment Center organized an interactive meeting on 24th Jan 2018 at Delhi on the eve of their country's Trade heads visit to India as guests for Republic Day. Council supported the event in inviting our members for attending the same.

MEETING WITH IRAN TRADE DELEGATION

A trade delegation from Iran comprising of some leading pharma companies visited Hyderabad on 24th February 2018. Pharmexcil organized a meeting with the delegation.

INTERACTIVE MEETING WITH UK MHRA OFFICIALS

During a visit to the office of Dy. High Commissioner, UK in Hyderabad, Council proposed a meeting with the UK MHRA officials with our members. Dy. High Commissioner suggested to organize an interactive meeting in Feb 2018 coinciding Bio Asia. Accordingly, Council organized an interactive meeting with UK MHRA officials for the benefit of pharma companies in Hyderabad on 26.2.2018. The event was well attended by the senior executives from the industry and regulators from Indian side.

WORKSHOPS ON GST/IGST/ITC PENDING REFUNDS & CORRECTIVE STEPS

For the benefit of member companies, Council organized a series of workshops at Ahmedabad, Mumbai and Delhi (9th, 20th March and 4th April 2018 respectively) on ' GST/IGST/ITC pending refunds and corrective steps. A senior consultant hired by Pharmexcil exclusively for this purpose, has helped the participants in understanding the problems in getting their GST/IGST refunds.

MEETING AT AHMEDABAD

MEETING AT MUMBAI

TECHNICAL SEMINAR AT VISAKHAPATNAM

At the instance of Department of Pharmaceuticals, Pharmexcil and IDMA jointly organized at Technical Seminar on ' Shifting Pharma industry from Schedule M to WHO compliance' at Vishakapatnam on 16th March 2018. The event was well attended by the local industry representatives.

ACCOUNTS FOR 2017-18

Accounts for 2017 - 18

INDEPENDENT AUDITOR'S REPORT

To

The Members of
M/s Pharmaceuticals Export Promotion Council of India
Hyderabad

Report on the Financial Statements

We have audited the accompanying financial statements of **M/s Pharmaceuticals Export Promotion Council of India ("the Company"),** which comprise the Balance Sheet as at 31st March, 2018, the Statement of Income And Expenditure Account, and a summary of the significant accounting policies and other explanatory information.

Management's Responsibility for the Standalone Financial Statements and for Internal Financial Controls over Financial Reporting

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit and to express an opinion on the Company's internal financial controls over financial reporting based on our audit.

We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act and the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement and whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

An audit involves performing procedures to obtain audit evidence about the amounts, the disclosures in the financial statements and adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exits, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting and the standalone financial statements.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial controls over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

(3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a

true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2018, and its surplus for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. As required by Section 143(3) of the Act, we report that:

   (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   (c) The Balance Sheet, the Statement of Income and Expenditure dealt with by this Report are in agreement with the books of accounts.

   (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

   (e) On the basis of the written representations received from the directors as on 31st March, 2018 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2018 from being appointed as a director in terms of Section 164 (2) of the Act.

   (f) In our opinion considering nature of business, size of operation and organizational structure of the entity, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2018, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

   (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

      i. The Company does not have any pending litigations which would impact its financial position.

      ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

      iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

   (h) The provisions of Companies (Auditors Report) Order, 2016 do not apply to the Company as it is licensed to be operated under Section 8 of the Companies Act and is hence exempted to be reported in accordance with clause 2(iii) of the said Order.

For and on behalf of
SARATH & ASSOCIATES
Chartered Accountants
FirmRegn No. 005120S



CA S Srinivas
Partner
M. No: 202471

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
(LIMITED BY GUARANTEE)
CIN : U24239TG2004NPL043058

BALANCE SHEET AS AT 31st March, 2018

Amount in Rs.

CORPUS FUND & LIABILITIES	SCH.	As at 31.03.2018	As at 31.03.2017
Corpus Fund		3,00,00,000	3,00,00,000
Reserves & Surplus	1	1,47,16,125	1,27,13,125
Advances from Govt.of India	2	3,73,506	1,15,85,641
Current Liabilities & Provisions	3	14,15,97,278	13,44,48,199
Excess of Income over Expenditure	4	15,67,70,192	11,22,40,408
		34,34,57,101	**30,09,87,373**

ASSETS	SCH.	As at 31.03.2018	As at 31.03.2017
Fixed Assets	5	2,39,50,173	64,91,090
Investments	6	16,78,52,770	13,92,55,583
Current Assets, Loans & Advances	7	15,16,54,158	15,52,40,701
		34,34,57,101	**30,09,87,373**

Vide our Report of Even Date
For SARATH & ASSOCIATES
FRN: 005120S
Chartered Accountants

CA S.SRINIVAS
Partner
M.No. 202471
Date: 18-06-2018
Place: Hyderabad

For Pharmaceuticals Export Promotion Council of India

Director General

Chairman

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
(LIMITED BY GUARANTEE)
CIN : U24239TG2004NPL043058

INCOME & EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31st March, 2018

Amount in Rs.

INCOME	SCH.	As on 31.03.2018	As on 31.03.2017
Membership Fees	8	4,39,29,800	4,20,53,406
Contributions from Members	9	18,36,56,272	20,34,21,557
Income from Investments	10	65,32,147	59,88,642
Other Income	11	14,87,035	1,17,09,630
Profit on sale of Asset		59,740	-
		23,56,64,994	**26,31,73,235**

EXPENDITURE	SCH.	As on 31.03.2018	As on 31.03.2017
Expenses on Coded Activities	12	14,23,14,767	16,98,59,590
Establishment Expenses	13	2,73,90,870	3,55,36,253
Other Administrative Expenses	14	2,02,79,383	3,12,07,671
Depreciation on Assets	5	11,50,190	10,15,766
		19,11,35,210	**23,76,19,280**
Surplus for the year carried to Schedule 1 A		**4,45,29,784**	**2,55,53,955**

Vide our Report of Even Date
For SARATH & ASSOCIATES
FRN: 005120S
Chartered Accountants

CA S.SRINIVAS
Partner
M.No. 202471
Date: 18-06-2018
Place: Hyderabad

For Pharmaceuticals Export Promotion Council of India

Director General

Chairman

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA

SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2018

Amount in Rs.

PARTICULARS		As at 31.03.2018		As at 31.03.2017
SCHEDULE - 1				
RESERVES & SURPLUS				
ENTRANCE FEE				
As per last Account	1,27,13,125		1,05,14,125	
Add: Entrance Fee collected from New Members	20,03,000	1,47,16,125	21,99,000	1,27,13,125
		1,47,16,125		**1,27,13,125**
SCHEDULE - 2				
(A) ADVANCE FROM GOVT.OF INDIA				
(I) Advances under MDA Scheme Refundable to the extent remaining unutilised				
As per last Balance Sheet	64,35,235		1,85,00,000	
Add: Received during the year	-		2,36,86,000	
	64,35,235		4,21,86,000	
Less: UTILISED BY THE COUNCIL				
(I) For Specific Code Activities	-		1,72,50,765	
(ii) Amount returned to Ministry	64,35,235		1,85,00,000	
	64,35,235	-	3,57,50,765	64,35,235
(II) Advances under Exporters MDA Claims Refundable to the extent remaining unutilised				
As per Last Balance Sheet	23,42,450		74,52,066	
Add: Received during the year	-		1,20,00,000	
	23,42,450		1,94,52,066	
Less: Amount returned to Ministry	-		89,36,740	
Less: MDA disbursed during the year	38,27,124		81,72,876	
	38,27,124	-14,84,674	1,71,09,616	23,42,450

Amount in Rs.

PARTICULARS		As at 31.03.2018		As at 31.03.2017
(III) Advances under MAI Scheme Refundable to the extent remaining unutilised				
As per Last Balance Sheet	28,07,956		2,28,42,149	
Add: Received during the year				
- Reimbursement of Product Regn. charges	-		19,05,21,688	
- Grants received for activities under MAI	6,11,28,235		8,74,58,315	
- Grants receivable for activities under MAI	-		-	
	6,11,28,235		30,08,22,152	
Less: Disbursed during the year				
- Returned to Ministry	1,08,221		40,12,902	
- Product Registration Charges	8,41,555		19,06,64,102	
- Utilised for Activities under MAI Scheme	6,11,28,235		10,33,37,192	
	6,20,78,011	18,58,180	29,80,14,196	28,07,956
(IV) Advances from Ministry of Chem & Fertilizers Refundable to the extent remaining unutilised				
GRANTS RECEIVED FOR IPR CELL				
As per last Balance Sheet	-		-	
Add: Received during the year	-		9,00,000	
Less: Utilised during the year	-	-	9,00,000	-
		3,73,506		**1,15,85,641**
SCHEDULE - 3				
CURRENT LIABILITIES & PROVISIONS				
Sundry Creditors for Expenses	2,45,96,345		3,26,24,387	
Outstanding Expenses	2,17,93,237		2,71,69,998	
GST Payable	41,65,004		-	
TDS Payable	5,43,488		32,46,314	
Advance Contributions from Members	9,04,99,204		7,14,07,500	
		14,15,97,278		13,44,48,199
		14,15,97,278		**13,44,48,199**
SCHEDULE - 4				
EXCESS OF INCOME OVER EXPENDITURE				
Opening Balance	11,22,40,408		8,66,86,453	
Add: Surplus as per Income & Exp. Account	4,45,29,784	15,67,70,192	2,55,53,955	11,22,40,408
		15,67,70,192		**11,22,40,408**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA

SCHEDULES TO THE ANNUAL ACCOUNTS FOR THE YEAR ENDED 31st March, 2018

SCHEDULE - 5

Schedule of Fixed Assets Annexed to and forming part of Balance Sheet as at 31-03-2018

Amount in Rs.

DESCRIPTION	GROSS BLOCK				DEPRECIATION BLOCK			NET BLOCK	
Particulars	Opening Balance 31.03-2017 Rs.	ADDITIONS DURING THE YEAR (>180) Rs.	ADDITIONS DURING THE YEAR(<180) Rs.	Closing Balance 31-03-2018 Rs.	Opening Balance 01-04-2017 Rs.	DEPRECIATION during the year Rs.	TOTAL DEPRECIATION UPTO 31-03-2018 Rs.	WDV ON 31-03-2018 Rs.	WDV ON 31-3-2017 Rs.
TANGIBLE ASSETS: OWN ASSETS:									
Lease Hold Land	5,58,302			5,58,302	-	-	-	5,58,302	5,58,302
Buildings		1,86,73,690		1,86,73,690	-	8,527	8,527	1,86,65,163	-
vehicles	48,78,098		2,60,260	46,17,838	19,37,771	4,37,498	23,75,269	22,42,569	29,40,327
Furniture & Fixtures	20,40,086			20,40,086	2,36,830	1,78,357	4,15,187	16,24,899	18,03,256
Office Eqipments	22,81,679	1,95,844		24,77,523	12,64,353	4,26,637	16,90,990	7,86,533	10,17,326
Computers	37,54,918	-		37,54,918	35,83,040	99,171	36,82,211	72,707	1,71,878
Intangible Assets - Software	2,87,111	-		2,87,111	2,87,111	-	2,87,111	-	-
Computers- IPR Cell	9,91,312	-		9,91,312	9,91,312	-	9,91,312	-	-
TOTAL	**1,47,91,506**	**1,88,69,534**		**3,34,00,780**	**83,00,417**	**11,50,190**	**94,50,607**	**2,39,50,173**	**64,91,089**

Amount in Rs.

PARTICULARS		As at 31.03.2018		As at 31.03.2017
SCHEDULE - 6				
INVESTMENTS				
Corpus FDR	3,00,00,000		3,00,00,000	
Other Fixed Deposits	13,78,52,770	16,78,52,770	10,92,55,583	13,92,55,583
		16,78,52,770		**13,92,55,583**
SCHEDULE - 7				
CURRENT ASSETS, LOANS & ADVANCES				
CURRENT ASSETS				
Cash in hand	1,99,510		1,45,754	
Bank Balance	6,84,68,827		6,69,48,736	
		6,86,68,337		6,70,94,490
LOANS & ADVANCES				
Rent Deposit	19,47,502		18,96,502	
Other Deposits	37,915		37,915	
Interest accrued on deposits	-		-	
TDS Receivable	3,29,15,005		2,79,95,367	
Advance for expenses	13,77,422		13,41,387	
Amount receivable for activities under MAI Scheme	2,31,41,763		1,85,87,978	
Sundry Debtors	1,62,00,116		1,74,51,273	
Advance to staff	4,46,474		4,65,229	
Brand Promotion Funds Receivable	52,06,839		52,06,839	
Advances paid for next year activities	15,38,589		1,47,79,860	
Service Tax	-		2,72,201	
Tour Advances to Staff	1,74,196	8,29,85,821	1,11,660	8,81,46,211
		15,16,54,158		**15,52,40,701**
SCHEDULE - 8				
MEMBERSHIP FEE				
Membership Fee	4,39,29,800	4,39,29,800	4,20,53,406	4,20,53,406
		4,39,29,800		**4,20,53,406**
SCHEDULE - 9				
CONTRIBUTION FROM MEMBERS				
Income from Exhibitions/Trade Fairs	8,62,15,679		12,98,88,247	
Income from Delegations	40,95,563		8,95,310	
Income from Reverse Delegations	9,07,18,555		7,17,09,500	
Income from Advertisements	26,26,475		9,28,500	20,34,21,557
		18,36,56,272		**20,34,21,557**

Amount in Rs.

PARTICULARS		As at 31.03.2018		As at 31.03.2017
SCHEDULE - 10 **INCOME FROM INVESTMENTS**				
Interest on Fixed Deposits				
- on fixed deposits with scheduled banks	65,32,147	65,32,147	59,88,642	59,88,642
		65,32,147		**59,88,642**
SCHEDULE - 11 **OTHER INCOME**				
Sale of Publications	61,000		11,200	
Certification Charges	1,69,960		1,52,990	
Other Income(including MAI processing charges)	12,56,075		1,15,45,440	
		14,87,035		**1,17,09,630**
SCHEDULE - 12 **EXPENSES ON CODED ACTIVITIES**				
Activities under MDA Scheme	-		3,98,54,214	
	-		**3,98,54,214**	
Activities under MAI Scheme	16,28,97,871		21,93,82,902	
	16,28,97,871		**21,93,82,902**	
Activities without Grant	5,53,74,526		4,96,70,193	
(A) : Expenses on Coded Activities	**21,82,72,397**		**30,89,07,309**	
Less: MDA Grants received from Govt.of India	-		1,72,50,765	
MAI Grants received from Govt.of India	7,59,57,630		12,17,96,954	
(B) : Total Grants	**7,59,57,630**		**13,90,47,719**	
(A) - (B)	**14,23,14,767**		**16,98,59,590**	
		14,23,14,767		**16,98,59,590**

Amount in Rs.

PARTICULARS		As at 31.03.2018		As at 31.03.2017
SCHEDULE - 13 **ESTABLISHMENT EXPENSES**				
Salaries	2,36,84,978		2,57,53,953	
Exgratia to Employees	13,70,246		18,22,928	
Medical Benefits to staff	4,65,944		6,15,825	
Staff Welfare Expenses	4,02,713		3,67,849	
L.T.A	-		13,76,337	
E.P.F Employer's Contribution	14,11,457		16,61,860	
Staff Leave Encashment	55,532		30,40,708	
Gratuity	-		8,96,793	
		2,73,90,870		**3,55,36,253**
SCHEDULE - 14 **OTHER ADMINISTRATIVE EXPENSES**				
Audit Fee	2,20,000		8,47,500	
Advertisement Expenses	1,96,000		98,000	
Bank Charges	42,195		3,96,284	
Books & Periodicals	61,877		59,286	
Building Maintenance	1,72,565		3,35,578	
COA Meeting Expenses	3,38,180		1,96,641	
Consultancy Charges	21,09,386		27,04,400	
Conveyance	13,93,182		11,91,348	
Electricity Charges	12,70,413		12,02,528	
Internet/Website	5,59,617		9,04,460	
Office Expenses	29,47,887		51,88,044	
Postage & Courier	4,19,935		5,20,126	
Printing & Stationery	4,15,762		6,60,091	
Rent	51,33,768		51,32,092	
Telephone	6,25,414		9,72,638	
Travelling Expenses	12,31,623		14,53,435	
Subscriptions for Export Data/Journals	17,32,758		55,895	
Exchange Rate Flucutuation	40,176		2,29,185	
Vehicle Maintenance	3,88,480		6,91,666	
Repairs & Maintenance	8,02,096		540497	
Debit/Credit balance written off	1,78,069		7402968	
Swach Bharath Cess	-		4,25,009	
		2,02,79,383		**3,12,07,671**

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA (LIMITED BY GUARANTEE)

CIN : U24239TG2004NPL043058

01 Company overview

PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA ("the Company"), a non profit company (hereinafter called the 'Council'), within the meaning of Section 8 of the Companies Act, 2013 (earlier Section 25 of the companies Act, 1956), was incorporated in India on the 1st day of April 2004 and by the virtue of Provisions of the Companies Act, the word "LIMITED" is not required to be suffixed in its name.

M/s Pharmexcil has been set up by the Ministry of Commerce and Industry to act as a Nodal Agency for issue of registration cum Membership certificates. Pharmaceutical exports through out the country under the provisions of foreign trade policy being announced by the Government of India from time to time.

02 Significant accounting policies

2.1 Basis of preparation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in India (Indian GAAP) to comply with the Accounting Standards specified under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and the relevant provisions of the Companies Act, 2013. The financial statements have been prepared on accrual basis under the historical cost convention. The accounting policies adopted in the preparation of the financial statements are consistent with those followed in the previous year unless stated otherwise.

2.2 Use of estimates

The preparation of the financial statements in conformity with Indian GAAP requires the Management to make estimates and assumptions considered in the reported amounts of assets and liabilities (including contingent liabilities) as on the date of financial statements and reported income and expenses during the year. The Management believes that the estimates used in preparation of the financial statements are prudent and reasonable. Future results could differ due to these estimates and the differences between the actual results and the estimates are recognized in the periods in which the results are known / materialized.

2.3 Investments

Long-term investments are carried individually at cost less provision for diminution, other than temporary, in the value of such investments. Interest on the same is being accounted for on accrual basis.

2.4 Tangible fixed assets

Fixed assets are stated at cost of acquisition including any cost attributable for bringing the assets to its working condition less accumulated depreciation .The cost of assets less accumulated depreciation up to the date of disposal are recognised in the Statement of Income and Expenditure.

2.5 Depreciation on Tangible fixed assets

Fixed Assets are stated at cost less accumulated depreciation. Cost includes all expenses related to acquisition and installation of the concerned assets and any attributable cost of bringing the asset to the condition of its intended use.

Depreciation on tangible assets is provided on the Straight line method by considering useful lives of assets specified in Schedule-II of the Companies Act 2013. Depreciation for assets purchased / sold during a period is proportionately charged.

2.6 Cash and cash equivalents

Cash and cash equivalents comprises cash on hand and cash in bank

2.7 Cash flow statement

Cash flows are reported using the indirect method, whereby surplus / (deficit) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

2.8 Employee benefits:

Defined contribution plans

The Company's contribution to provident fund, superannuation fund and National Pension Scheme are considered as defined contributionplans and are charged to the Statement of Income and Expenditure as they fall due, based on the amount of contribution required to be made and when services are rendered by the employees.

2.9 Revenue recognition

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured and Entry fee collected is credited to General Reserve directly.

2.10 Operating leases

Leases under which all the risks and benefits of ownership are effectively retained by the lessor are classified as operating leases. Amount due under the operating leases are charged to the Statement of Income and Expenditure, on a straight-line method, over the lease term in accordance with Accounting Standard 19 on 'Leases'. Initial direct costs incurred specifically for operating leases are recognised as expense in the year in which they are incurred.

2.11 Foreign currency transactions and translations

Transactions in foreign currencies of the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction. Foreign currency monetary items outstanding at the Balance Sheet date are reported using the closing rate. Gain or loss resulting from the settlement of such transactions and translations of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Income and Expenditure.

2.12 Provisions and contingencies

A provision is recognised when the Company has a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the balance sheet date. These are reviewed at each balance sheet date and adjusted to reflect the current best estimates.

2.13 GST input credit

GST input credit is accounted for in the books in the period in which the underlying service received is accounted and where there is reasonable certainty in availing/utilizing the credits.

2.14 The Balances of Sundry Debtors, Sundry Creditors and Loans and Advances are subject to confirmation and consequential adjustments , if any required.

2.15 In the opinion of the management, the Current Assets, Loans and Advances have a value on realization in the ordinary course of business,equal to or at least to the aggregate amount shown in the Balance Sheet

2.16 Recognition of Grants:

The expenses in respect of Code activities are subject to Sanction/Confirmation of the Government of India and Grant- in- aid received from the Ministry of Commerce is subject to the adjustments on account of Government Audit objections, if any, partial/ non fulfillment of conditions laid down for eligibility of such Grant-in-aid, clarification by M/s Pharmaceuticals and the final decision of the Ministry in respect of the same shall be followed.

2.17 Taxes on Income:

Tax expense comprises current year income tax, deferred income tax charges or credit and MAT/ credit Entitlement for the year.

- Current year income tax charge will be calculated based on assessable profits of the company determined in accordance with the provisions of Income Tax Act, 1961. It also includes, income tax charge provided if any, for such disallowances made on completion of assessment proceedings pending appeals, as considered appropriate depending on the merits of each case.
- Minimum Alternate Tax (MAT) credit is recognized, as an Asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified year. In the year in which the Minimum Alternate tax (MAT) credit becomes eligible to be recognised as an asset in accordance with the recommendation contained in Guidance Note issued by the Institute of Chartered Accountants of India, the said asset is created by way of a credit to the Statement of profit and loss and shown as MAT Credit Entitlement.Such Assets are reviewed as at each Balance Sheet and written down to reflect the amount that will not be available as a credit to be set off in future, based on the applicable taxation law then in force.

3 NOTES FORMING PART OF THE BALANCE SHEET AND PROFIT &LOSS ACCOUNT

3.1Related parties Disclosures: Disclosures as required by Accounting Standard (AS) -18 " Related Party Disclosures" notified under the Companies (Accounting Standard) Rules , 2006 is given below.

Name of the related parties, their relationships with council and with whom transactions entered during the year :

i. Entities in which the member of the Committee of Administration is interested and nature of interest.

Committee Member	Entity in which Committee Member is interested	Nature of interest
Mr. Madan Mohan Reddy	Aurobindo Pharma Ltd	Director
Mr. Devang B Shah	Aadivighnesh Chem Pvt Ltd	Director
Mr. Bharat Desai	Bharat Parenterals Ltd	Managing Director
Mr. Tushar A Korday	Emil Pharmaceutical Industries Pvt Ltd	Director
Mr. A R Venkatesh	Global Pharma Healthcare Pvt Ltd	Chief Executive Officer
Mr. Sahil Munjal	Ind-Swift Laboratories Ltd	President & Chief Executive Officer
Mr. Dinesh Dua	Nectar Life Sciences Ltd	CEO & Director
Mr. Atul Bhopale	Nexgen Healthcare Pvt Ltd	Executive Director
Mr. Janmejay H Patel	Petlad Mahal arogya Mandal Pharmacy	Chief Executive Officer
Mr. Vijay Shah	Stallion Laboratories Pvt ltd	Managing Director
Mr. Sandeep V Bambolkar	Indoco Remedies Ltd	Jt. Managing Director
Mr. P Ramesh Babu	SMS Pharmaceuticals Ltd	Chairman & Managing Director
Mr. Dodda VVS Reddy	Nosch Labs Ltd	Director
Mr. Siddharth Daga	Vins Bioproducts Ltd	Executive Director
Mr. Bhavin Patel	Mediwin Pharmaceuticals	Partner
Mr. Fazal Abbas Virji	Shalina Laboratories Pvt Ltd	Director

ii. Details of Key Managerial Personnel:

Mr. Udaya Bhaskar – Director General

Mr.Raghuveer Kini – Executive Director

iii. Remuneration to Directors:

During the Current Financial Year 2017-18, Remuneration to Mr.Udaya Bhaskar, Director General Rs.37,93,375/- Mr.Raghuveer Kini, Executive Director's Remuneration Rs.32,34,546/-

iv. The following are the disclosure in respect of Material Related Party Transactions during the year :

Company Name	Membership Fee in Rs.	Amount received for Exhibitions/ BSMs	MAI Processing Charges in Rs.
Aurobindo Pharma Ltd	-	13627	-
Aadivighnesh Chem Pvt Ltd	-	2360	-
Bharat Parenterals Ltd	25960	1307940	-
Emil Pharmaceutical Industries Pvt Ltd	57500	463297	-
Global Pharma Healthcare Pvt Ltd	11500	285040	-
Ind-Swift Laboratories Ltd	56640	-	-
Nectar Life Sciences Ltd	42480	4720	-
Nexgen Healthcare Pvt Ltd	-	-	-
Petlad Mahal arogya Mandal Pharmacy	34500	-	-
Stallion Laboratories Pvt ltd	-	186440	-
Indoco Remedies Ltd	-	-	-
SMS Pharmaceuticals Ltd	41400	207000	-
Nosch Labs Ltd	23300	1661400	-
Vins Bioproducts Ltd	-	1548660	-
Mediwin Pharmaceuticals	11800	76180	-
Shalina Laboratories Pvt ltd	42480	5870	-
Total	**347560**	**5762534**	**-**

3.2 Details Regarding Advances during the year :

Unutilized MDA Advance at the beginning of the Year is Rs.64,35,235/- (Previous year Rs.1,85,00,000/-) and during the year under review, the amount of Advance received from Ministry of Commerce under this head stood at Rs.NIL (previous year Rs.2,36,86,000/-). During the Current Year an amount of Rs.NIL has been utilized (previous year Rs.1,72,50,765) and Balance Rs.64,35,235/- returned to Ministry

3.3 Pursuant to the approval by the Ministry of Commerce for Grant of Marketing Development Assistance (MDA) to Individual exporters under certain eligible scheme, M/s Pharmexcil has received during the year an amount of Rs. NIL (previous year Rs. 1,20,00,000) and the amount Reimbursed to members stood at Rs.38,27,124/- (previous year Rs. 81,72,876/-).

3.4 During the year under review, an amount of Rs.NIL(previous year Rs.19,05,21,688)was received for reimbursement of Product Registration Charges under MAI Scheme, and the amount disbursed during the year was Rs.8,41,555(previous year Rs.19,06,64,102).

3.5 Unutilized MAI advance of the beginning of the year stood at Rs.28,07,956 (previous year Rs.2,28,42,149) and during the year under review, the amount of advance received from Ministry of Commerce under this head stood at Rs. 6,11,28,235/-(previous year Rs.8,74,58,315). As against this the amount utilized by the Council was Rs.6,11,28,235/- (previous year Rs.10,33,37,192/-).

3.6 DUES OF MICRO AND SMALL ENTERPRISES:

The information as required to be disclosed under Schedule III of the Act, w.r.t. Micro and Small Enterprises under the Micro, Small and Medium Enterprises Development Act, 2006 (Act) is as given below and the information mentioned to Trade Payables w.r.t. dues of Micro and Small Enterprises, has been determined to the extent such parties have been identified on the basis of information available with the Company and relied on by the auditors:

Particulars	2017-18	2016-17
a. Principal amount remaining unpaid as on 31st March	NIL	NIL
b. Interest due thereon as on 31st March	NIL	NIL
c. Interest paid by the Company in terms of Section 16 of Micro, Small and Medium Enterprises Development Act, 2006, along with the amount of payment made to the supplier beyond the appointed day during the year	NIL	NIL
d. Interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year but without adding the interest specified under the Act)	NIL	NIL
e. Interest accrued and remaining unpaid as at 31st March	NIL	NIL
f. Further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the Act.	NIL	NIL

3.7 Membership Fees was accounted on Receipt basis and accordingly, no Provision for Membership has been made for the year end.

3.8 Provisions

Taxes on Income:

Pharmexcil has been registered under Section 12AA of Income Tax Act,1961 which is not required to pay tax subject to fulfillment of necessary conditions laid there on.

4.0 Provision for Auditors Remuneration :

Particulars	Audit Fee for the year (₹)	Service Tax there on (₹)	Total Amount (₹)
Statutory Auditors	100000	18000	118000
Internal Auditors	120000	21600	141600

4.1 Provision for Gratuity:

During the current financial year 2017-18, the Company has not provided for Gratuity.

4.2 Additional Information as required under Part-II of Schedule III of the Companies Act, 2013.

The following is the expenditure in the Foreign Currency during the financial year 2017-18:

Particulars	Amount	Amount (₹)
Expenditure in Foreign Currency	US($) 1050614	6,96,56,599
	Euro($) 377941	2,92,45,684
	JPY 6961680	45,32,147
	RMB53500	548043

4.3 Figures have been rounded off to the nearest rupee and previous figur**es are regrouped/reclassified wherever necessary to confirm to the current year classification.**

Vide our Report of Even Date
For SARATH & ASSOCIATES
FRN: 005120S
Chartered Accountants

CA S. SRINIVAS
Partner
M.No. 202471
Date: 18-06-2018
Place: Hyderabad

For Pharmaceuticals Export Promotion Council of India

Director General

Chairman

CIRCULARS & TRADE ENQUIRIES

List of Circulars for the Year 2017-18

S. No	Date	Subject
1	06-Apr-17	Visit iPHEX - Meet Senior officials FDAs/Health Ministries of over 20 countries
2	11-Apr-17	Technical Sessions during 27th -28th April, 2017, 5th Edition of iPHEX 2017 at HITEX, Hyderabad
3	12-Apr-17	Postponed / Deferred - Seminar on "Pharma Exports - Challenges & Opportunities" at Ahmedabad on 13th April 2017
4	13-Apr-17	Public comments invited by China food & Drug Administration (CFDA) on Draft Notification - "Decision on Adjusting Matters Concerning the Registration Management of Imported Drugs" by 20th April 2017
5	05-May-17	NPPA now regulates the prices of Coronary Stents
6	09-May-17	Visit of High-level delegation to Ecuador and Columbia 16-19 May 2017
7	12-May-17	5th Session of India-Morocco Joint Commission Meeting (JCM) scheduled to be held on 25-26th May, 2017 at Rabat, Morocco
8	15-May-17	Pharmexcil Pavilion in CPhI Worldwide, 24-26 October 2017 at Messe Frankfurt, Germany
9	16-May-17	Important discussions / decisions about various Banking related issues
10	21-May-17	Procurement of Generic Medicines by Fiji
11	22-May-17	India Pavilion at CPhI India 2017 at Mumbai
12	25-May-17	IPA (Telangana State Branch) in organizing Symposium with the support of AIDCOC & Pharmexcil on “Regulator to Facilitator” on Saturday, 10th June 2017 at Radisson Blue Hotel, Banjara Hills, Hyderabad from 10:00 am to 5:00 pm.
13	26-May-17	Rescheduled dates - Dakar International Expo on Health and Medical Equipment -19th to 22nd July2017
14	27-May-17	Procurement of Medicines by Syria
15	30-May-17	Two Stalls Available - India Pavilion at CPhI China - 20-22nd June 2017
16	05-Jun-17	Banking related issues
17	08-Jun-17	Implementation of GST specific issues relating to Drugs & Pharmaceuticals Sector
18	09-Jun-17	Pharmexcil Awards for Outstanding Export Performance for the year 2016-17 Invitation for Applications
19	10-Jun-17	Business Delegation to Colombia, El-Salvador and Costa Rica followed by IPHEX-LATAM in Peru (22nd August - 6th September 2017)
20	11-Jun-17	IDMA TS chapter with the support of Pharmexcil is organizing Seminar on "GST - Implementation by Pharma Industry" on Monday, 19th June 2017, Hyderabad
21	12-Jun-17	VENDOR REGISTRATION DETAILS OF PHARMEXCIL FOR GST
22	13-Jun-17	Seminar on Goods and Service Tax (GST) - Impact on Pharma Sector in Mumbai on 27th June 2017

23	15-Jun-17	Launch of Medical Devices Park by Telangana State Government
24	16-Jun-17	Catalogue Show at Saudi Arabia
25	20-Jun-17	Important Trade Notice Issued by DGFT - Changes in IEC with introduction of GST
26	21-Jun-17	Seminar on Goods and Service Tax (GST) - Impact on Pharma Sector in Mumbai on 27th June 2017 at “Sunville Banquets”, Worli, Mumbai – 400 018
27	30-Jun-17	Export Award Circular Amendment - Last Date for receipt of Self-Nomination advanced
28	07-Jul-17	Business Delegation to Colombia, El-Salvador and Costa Rica followed by IPHEX-LATAM in Peru (27th August – 9th September 2017)
29	08-Jul-17	Proposal for setting up Joint Pharmaceutical venture at Chelyabinsk region of Russian Federation
30	10-Jul-17	Handling of Iran based Export Import Trade Transactions in EURO & INR by IndusInd Bank - reg
31	10-Jul-17	Interactive meeting with Senior Officials from Ministry of Commerce on 17th July 2017 at Hyderabad -Proposal for setting up Joint Pharmaceutical Venture at Chelyabinsk Region of Russian Federation
32	14-Jul-17	POST GST ISSUES AT PHARMEXCIL
33	21-Jul-17	Additional Space for API in Hall 10.1 at CPhI Worldwide, 24-26th October 2017, Messe Frankfurt, Germany-Stall Reservation opens at 4:30 pm today.
34	24-Jul-17	Innovation Desk at Pharmexcil
35	28-Jul-17	Opportunity for SMEs to participate in CPhI Worldwide from 24-26th October 2017, Messe Frankfurt, Germany
36	28-Jul-17	Interactive Meeting with Antwerp Port, Belgium
37	02-Aug-17	Training Programme on "Foreign Trade with GST Perspective" conducted by PHARMEXCIL on 11th August, 2017 at Mumbai
38	04-Aug-17	Export Award Circular Amendment - Last Date of receipt of applications extended to 23rd August 2017
39	04-Aug-17	Registrations Closed - Training Programme on Foreign Trade with GST Perspective on 11th August 2017 at Mumbai
40	07-Aug-17	Training Programme on "Foreign Trade with GST Perspective" conducted by PHARMEXCIL on 22nd August, 2017 at New Delhi
41	12-Aug-17	iPHEX-2018: Bookings open for 6th Edition, 08-10 May 2018, Pragati Maidan, New Delhi
42	16-Aug-17	Notice for Extra-Ordinary General Meeting
43	24-Aug-17	Survey on Assessing the Impact of Non-Tarrif Measures on Trade between ASEAN and India-Conducted by ASEAN-India Centre
44	25-Aug-17	Business Delegation to Cuba and Panama (29th October -3rd Nov 2017)
45	29-Aug-17	Interactive meeting under DGFTs Niryat Bandhu Initiative
46	29-Aug-17	Block Your Diary - 13th Annual Meet - 23rd September 2017
47	05-Sep-17	Training Programme on Foreign Trade with GST Perspective, Bengaluru
48	06-Sep-17	Free Distribution of Catalogues at PHARMAFRICA EXPO 2017

49	06-Sep-17	Upgradation of India-Korea CEPA-Seeking inputs on tariff lines and Rules of Origin
50	07-Sep-17	Indigenous Technology developed by ICMR for production of Key Starting Material for TAMIFLU
51	08-Sep-17	Interactive Meeting with RBI officials on EDPM System and Procedure for delisting from caution list - 13.09.2017
52	08-Sep-17	India Pavilion at Arab Health - 29th January - 1st February 2018, Dubai, UAE
53	08-Sep-17	Notice for13th Annual General Meeting
54	09-Sep-17	Venue Changed - Training Programme on "Foreign Trade with GST Perspective"- Bengaluru
55	10-Sep-17	Public invitation for sale of State owned Galenika Pharmaceuticals of Serbia - reg
56	11-Sep-17	Invitation to CEOs/ R& D Heads - Crucible to Market - A Roundtable Conference
57	11-Sep-17	Review of countervailing duty against import of Dicloxacillin Sodium from India to Mexico
58	13-Sep-17	Invitation for Success Stories - Global Entrepreneurship Summit 2017 (GES-2017) from 28-30 November 2017 at Hyderabad
59	14-Sep-17	Technical Seminar "Risk Management Strategy for Pharma Industry Going Forward" 23rd September 2017 - Hyderabad
60	21-Sep-17	Invitation - 13th Annual Meet of Pharmexcil
61	21-Sep-17	Invitation to CEOs/R&D Heads: Round Table Conference on APIs, KSMs & Intermediates (Product development)
62	25-Sep-17	Submission of Pre-Budget Proposals for the Year 2018-19
63	03-Oct-17	Business Delegation to Cuba and Panama
64	05-Oct-17	Block Your Diary: International Arogya, 04-07 December 2017
65	06-Oct-17	3rd India Pharma/Medical Device Awards : Nominations called by Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India
66	06-Oct-17	Visit of High-Level Delegation from Iraq - 8-14th October 2017
67	07-Oct-17	Avail the opportunity of advertising in Show Catalogue of CPhI India 2017
68	08-Oct-17	Applications for Reimbursements under MAI scheme for 2015-16
69	09-Oct-17	Conference on "Chemical & Industrial Disaster Management" from 11-13 Oct.2017 at ITC Kakatiya Hotel, Hyderabad
70	09-Oct-17	Avail the opportunity of advertising in Show Catalogue of CPhI Worldwide 2017
71	10-Oct-17	Interactive Meeting with Delegation from Iraq - 12th October 2017, New Delhi
72	13-Oct-17	Market & Regulatory Information of some Developed and Emerging Markets
73	13-Oct-17	Business Delegation to Russia, Ukraine, Belarus and Uzbekistan
74	18-Oct-17	Interactive Meeting with Merchant Exporters from Pharma Sector
75	18-Oct-17	IGST PENDING CLAIMS
76	19-Oct-17	A Happy and Prosperous Diwali
77	25-Oct-17	Interactive meeting on GST - 3rd November 2017 at Hyderabad
78	25-Oct-17	3rd India Pharma/Medical Device Awards

79	28-Oct-17	Customer Grievance Camp during 30.10.2017 to 04.11.2017 to attend to the grievances of the trade with regard to Vigilance and corruption at Mumbai
80	10-Nov-17	Postponed / Deferred - Business delegation to Russia, Ukraine and Uzbekistan during 4th December 2017 to 16th December 2017
81	17-Nov-17	India Pavilion at CPhI-Tokyo, Japan from 18-20th April, 2018
82	21-Nov-17	Investment Opportunities in Uzbekistan
83	23-Nov-17	PHARMEXCIL - URGENT FEEDBACK ON DELAYED REFUND OF GST
84	25-Nov-17	Joint venture proposal from a Company IMKONIYAT SAKHOVAT, Tashkent, Uzbekistan - Reg
85	25-Nov-17	BSMs in DCR Congo, Nigeria and Cote d Ivoire 18-28 February 2018
86	27-Nov-17	INTERNATIONAL AROGYA, 4-7 DECEMBER 2017, New Delhi
87	27-Nov-17	A Joint Seminar with DoP and IDMA - TS Board on 08 December 2017
88	28-Nov-17	Interactive Meeting with High Level Delegation from Cuba, 07 Dec 2017, New Delhi
89	29-Nov-17	BSM-CUM-Expo in Yangon, Myanmar followed by BSM in Vietnam and Indonesia (10 Jan - 21 Jan 2018)
90	01-Dec-17	Refund of IGST paid for Exports at Chennai Customs
91	12-Dec-17	Pharmaconex, Cairo, Egypt - 14-16th April 2018
92	13-Dec-17	Major Political & Economic Reforms initiated in Uzbekistan
93	14-Dec-17	Update on Foreign Trade Policy (FTP) 2015-20 - For assistance of our member-Exporters
94	14-Dec-17	BSM-CUM-Expo in Yangon, Myanmar followed by BSM in Vietnam and Indonesia (10th Jan-21st Jan 2018)
95	15-Dec-17	Promote your Products in Middle East Countries - Advertise in Show Catalogue of Arab Health 2018
96	18-Dec-17	Last date for ASEAN delegation extended till 21st December 2017 - Expo cum BSM at Myanmar, Vietnam, and Indonesia
97	22-Dec-17	Postponed/Deffered - BSM-CUM-Expo in Yangon, Myanmar followed by BSM in Vietnam and Indonesia
98	28-Dec-17	Issue of Certificate of Origins (COOs) by Delhi & Ahmedabad Offices
99	29-Dec-17	India - Peru - Free Trade Agreement
100	05-Jan-18	Inviting issues/suggestions while exporting pertaining to Sri Lanka and Taiwan
101	11-Jan-18	Important Public notices no 34, 35, 36 and 37 issued by DGFT, New Delhi
102	18-Jan-18	PHARMEXCIL PHILIPPINES, India Business Forum with Secretary Ramon M. Lopez, Minister, An Exclusive Invitation on 24 January 2018, 5-7pm at The Lalit, New Delhi
103	22-Jan-18	Accelerate-International Business Connect on 23rd Jan.2018 at Taj Vivanta, Begumpet, Hyderabad
104	24-Jan-18	Asia Pharma Expo 2018 from 8-10th February 2018 at Dhaka, Bangladesh
105	25-Jan-18	GST Refund - Appointment of Nodal Officers & Guide on IGST Refunds in ICEGATE
106	03-Feb-18	India Pavilion at CPhI China, 20-22 June 2018
107	04-Feb-18	15th Edition of BioAsia, 22-24 February 2018

108	05-Feb-18	Floor Plan-CPhi China 2018-Reserve your stand
109	06-Feb-18	Submission of EXPORT RETURNS Quarterly in accordance to para 2.96 of Handbook of Procedures of Foreign Trade Policy 2015-20-reg
110	07-Feb-18	The Pharma CIO Leadership Series on 20th Feb.2018 at Courtyard by Marriott, Mumba
111	07-Feb-18	RCMC RENEWAL ALERT
112	08-Feb-18	Requirement of Medicines by PDVSA Health, Venezuela
113	13-Feb-18	Participate in KOREA PHARM 2018 South Korea, 17-19 April 2018
114	13-Feb-18	Interactive Meeting with UKMHRA Officials on 26th Feb.2018 at Taj Deccan, Hyderabad, organized jointly by Pharmexcil and British High Commission, Hyderabad
115	14-Feb-18	Elections to the Committee of Administration - Enroll as Eligible Voter
116	01-Mar-18	Workshop on "GST/IGST/ITC pending refunds & corrective steps" conducted by PHARMEXCIL on 09th March, 2018 in Ahmedabad, Gujarat
117	05-Mar-18	Extension of last date for enrollment as Eligible Voter
118	05-Mar-18	Technical Seminar jointly organized with Indian Drug Manufacturers' Association (IDMA), Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Government of India and Pharmexcil in Visakhapatnam, Andhra Pradesh.
119	06-Mar-18	Workshop on "GST/IGST/ITC pending refunds & corrective steps" Conducted by Pharmexcil
120	06-Mar-18	Renewal of RCMC for 2018-19
121	07-Mar-18	Attn: Exporters to Mozambique Mandatory Pre-shipment Inspection
122	08-Mar-18	Revised: Participation in CPhI-Tokyo, 18-20th April, 2018 SUPPORT TO EXHIBITORS UNDER MAI SCHEME
123	08-Mar-18	Workshop on "GST/IGST/ITC pending refunds & corrective steps" Conducted by Pharmexcil in MUMBAI
124	09-Mar-18	Request for Participation in IPHEX-2018, 8-10 May 2018, Vigyan Bhawan and Pragati Maidan, New Delhi
125	16-Mar-18	CBEC announces GST camps from 15th March 2018 to fast track GST Refund to exporters - reg
126	19-Mar-18	Information from Life Sciences Sector Skill Development Council (LSSSDC) as an Industry-led Skill Certification Body is shared hereby- Reg.
127	20-Mar-18	Appointment of ADC (I) at Visakhapatnam Air/Sea Port
128	21-Mar-18	Workshop on GST/IGST/ITC pending refunds & cirrectuve steos cibdycted by Pharmexcil on 4th April 2018 at New Delhi
129	22-Mar-18	Removal of Requirement of NOC from Port Offices of CDSCO
130	23-Mar-18	Greater Market Access for Indian Pharmaceutical products and medical equipment in the Chinese market
131	28-Mar-18	Elections to 16 (sixteen) seats of Committee of Administration for 2018-20 - Nominations invited
132	31-Mar-18	Election Notification - Clarifications

List of Trade Enquiries for the Year 2017-18

Sl No	Date	Subject
1	11-Apr-17	Trade Enquiry - Sri Lanka
2	22-Apr-17	Trade Enquiry – Mozambique
3	3-Jul-17	Trade Enquiry - South Korea
4	6-Jul-17	Trade Enquiry - Indonesia
5	31-Jul-17	Trade Enquiry - Philippines
6	1-Aug-17	Trade Enquiry - Sri Lanka
7	17-Aug-17	Trade Enquiry - Uzbekistan
8	18-Aug-17	Trade Enquiry - Myanmar
9	8-Sep-17	RFQ for products by CENARES, Lima, Peru
10	26-Sep-17	Trade Enquiry - Togo, Africa
11	12-Oct-17	Trade Enquiry - Sri Lanka
12	8-Nov-17	Trade Enquiry - Egypt
13	5-Dec-17	Tender Enquiry - Ethiopia
14	6-Dec-17	Trade Enquiry - Togo, Africa

BENEFICIARIES UNDER MAI SCHEME

Beneficiaries under MAI Scheme 2017-18

S. No	Name of the Company	Name of the Event	Amount
1	Angiplast Pvt Ltd	Latam (Columbia, Elsalvador, peru)	100000
2	Hexagon Nutrition pvt Ltd	Latam (Columbia, Elsalvador, peru)	100000
3	Lactose India Ltd	Latam (Columbia, Elsalvador, peru)	100000
4	Nem Laboratories Pvt ltd	Latam (Columbia, Elsalvador, peru)	100000
5	Riocare India pvt Ltd	Latam (Columbia, Elsalvador, peru)	100000
6	Siddharth International	Latam (Columbia, Elsalvador, peru)	100000
7	Vaishali Pharma pvt Ltd	Latam (Columbia, Elsalvador, peru)	100000
8	Verve Humancare Laboratories	Latam (Columbia, Elsalvador, peru)	100000
9	Virchow healthcare Pvt ltd	Latam (Columbia, Elsalvador, peru)	100000
10	Hexagon Nutrition pvt Ltd	CPhI WW 2017	63500
11	JPN Pharma Pvt Ltd	CPhI WW 2017	48501
12	Medilink Pharmachem	CPhI WW 2017	70000
13	Metina Pharm Consulting	CPhI WW 2017	70000
14	NB Entrepreneurs	CPhI WW 2017	70000
15	Rio Care (India) Pvt Ltd	CPhI WW 2017	70000
16	Shashi Phytochemical Industries	CPhI WW 2017	70000
17	Shreeji Pharma International	CPhI WW 2017	44850
18	Spansules pharmatech pvt ltd	CPhI WW 2017	61098
19	Supreem Pharmaceuticals Mysore Pvt Ltd	CPhI WW 2017	50963
20	Surya Organics & Chemicals	CPhI WW 2017	50500
21	sydler Remedies Pvt Ltd	CPhI WW 2017	50217
22	West-Coast Pharmaceutical Works Ltd.	CPhI WW 2017	53118
23	Zenova Bio Nutriton Pvt Ltd	CPhI WW 2017	61098
24	3S Corporation	Arab Health 2017-18	13570
25	Aligns International	Arab Health 2017-18	17709
26	Asoj Soft Caps Pvt Ltd	Arab Health 2017-18	22940
27	Babuline Pharma Pvt. Ltd.	Arab Health 2017-18	18563
28	Beta Surgicare Pvt. Ltd.	Arab Health 2017-18	21456
29	Dynamic Ortho Industries	Arab Health 2017-18	13806
30	Genex Pharma	Arab Health 2017-18	20065
31	Hiral Labs Ltd.	Arab Health 2017-18	13991
32	Livealth Biopharma Pvt Ltd	Arab Health 2017-18	17705
33	Medsource Ozone Biomedicals	Arab Health 2017-18	17805
34	Meridian Enterprises Pvt Ltd	Arab Health 2017-18	19200

35	Nature'S Global Service	Arab Health 2017-18	17088
36	Nebula Surgical Pvt Ltd	Arab Health 2017-18	27250
37	Palakkad Surgical Industries Pvt. Ltd.	Arab Health 2017-18	18081
38	Pv Pharma Healthcare Pvt Ltd	Arab Health 2017-18	30645
39	Regal Laboratories	Arab Health 2017-18	25450
40	Sydler Remedies Pvt Ltd	Arab Health 2017-18	15229
41	Terrace Pharmaceuticals Pvt Ltd	Arab Health 2017-18	13991
42	Verve Human Care Laboratories	Arab Health 2017-18	36694
43	Wellmed International Industries Pvt Ltd	Arab Health 2017-18	19402
44	West-Coast Pharmaceutical Works Ltd.	Arab Health 2017-18	26100
45	Xcellance Medical Technologies Pvt Ltd.,	Arab Health 2017-18	12159
46	Yashica Pharmaceuticals Pvt. Ltd.	Arab Health 2017-18	18432
47	Zenova Bio Nutrition Pvt. Ltd.	Arab Health 2017-18	22995
48	Apex Drug House	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
49	Asoj Soft Caps Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
50	Claps Industries Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
51	Corona Remedies pvt ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
52	Digital Vision	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
53	Endurance Healthcare Ltd.	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
54	Globela Pharma Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
55	Hexagon Nutrition Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
56	Hiral Labs Ltd.	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
57	Maan Pharmaceuticals Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
58	Mediwin Pharmaceuticals	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
59	Medsource Ozone Biomedicals Pvt. Ltd.,	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
60	Nectar Laboratories Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
61	Nej Biotech	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
62	Pharmaworld International	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
63	Regal Laboratories	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
64	Sneha Medicare Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
65	subhra pharma pvt ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
66	Sunij Pharma Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
67	Surgeway Biosciences	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
68	Tanmed Pharma India Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
69	Terrace Pharmaceuticals Pvt Ltd	BSM Africa (Congo-Nigeria-Cote-d Ivoire)	70000
70	Viola Healthcare Pvt. Ltd.	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
71	Wintech Pharmaceuticals	BSM Africa (Congo-Nigeria-Cote-d Ivoire	70000
		Total	3894171

Pharmaceuticals Export Promotion Council of India

(Setup by Ministry of Commerce & Industry, Govt. of India)

Head Quarters / Regd. Office :

101, Aditya Trade Center, Ameerpet, Hyderabad – 500 038.
Ph: 91-40-23735462/66, Fax: 91-40-237375464
E-mail: info@pharmexcil.com

Regional Office - Mumbai :

TV Industrial Estate, Unit No. 211, 2nd Floor, 248-A S.K. Ahire Marg, Worli, Mumbai - 400 030.
Ph: 91-22-24938750/51/58/59, Fax: 91-22-24938822
E-mail: romumbai@pharmexcil.com

Regional Office - New Delhi :

H.28, 2nd Floor, 23 Himalaya House, K.G. Marg, Connaught Place, New Delhi - 110 001.
Ph: 91-11-41536654 / 45062550 Fax: 91-11-41536658
E-mail: rodelhi@pharmexcil.com

Branch Office - Ahmedabad :

7-C, Trade Centre, Near Stadium Cross Road, Navarangpura, Ahmedabad – 380 009.
Ph: 91-79-40050497 E-mail: boahmedabad@pharmexcil.com

Website: www.pharmexcil.com